Medicines Healthcare Products Regulatory Agency
Details
Information about COVID-19 Vaccine SKYCovion approved by the MHRA on 26 May 2022.
The Summary of Product Characteristics is a description of a medicinal products properties and the conditions attached to its use. It explains how to use and prescribe a medicine. It is used by healthcare professionals, such as doctors, nurses and pharmacists.
The Patient Information Leaflet provides information for patients on using the medicine safely. This is based on the Summary of Product Characteristics of the product.
This Marketing Authorisation granted by the MHRA is valid in Great Britain.
See further information in ournews story.
Ingredients
The MHRA can confirm that COVID-19 Vaccine SKYCovion does not contain any excipients of animal origin.
A full list of ingredients for the qualitative and quantitative composition of the vaccine can be found atpoint 2 in the Summary of Product Characteristics for COVID-19 Vaccine SKYCovion.
A full list of ingredients for the excipient composition of the vaccine can be found atpoint 6.1 in the Summary of Product Characteristics for COVID-19 Vaccine SKYCovion.
A full list of ingredients for the qualitative and quantitative composition of the vaccine and a full list of the excipient composition of the vaccine can be found atpoint 6 in the Patient Information Leaflet for COVID-19 Vaccine SKYCovion.